FABASOFT
29.3.2021 15:35:10 CEST | Business Wire | Press release
Fabasoft, a leading European provider of cloud solutions, was invited by Forrester to take part in an independent overview of “Content Platforms” (“The latest stage of evolution in the market traditionally known as Enterprise Content Management Systems”).
Research and advisory firm Forrester Research Inc. overviewed 38 top cloud content platforms based on platform capabilities, vertical focus, and size.
One of the key takeaways according to the authors of the “Now Tech: Content Platforms, Q1 2021” analysis* indicates that “…small and midsize vendors may offer a better range of content services and expertise in specific vertical markets.” Yet the study’s authors also offer the following words of caution: “Be wary of ‘cloudwashing’ when older technologies are hosted but branded as cloud.”
The functionality of Fabasoft Business Process Cloud as a multi-client cloud content platform covers categories addressed in the study such as “Collaborative Content Services” and “Transactional Content Services and Multitenant Cloud Content Platforms.”
Download now: Now Tech: Content Platforms, Q1 2021
“We believe being listed in the report as a native cloud provider with three of the four primary functionality segments attests to the capabilities and performance of the Fabasoft Business Process Cloud,” remarks a delighted Andreas Dangl, Business Unit Executive Cloud and digitalization expert at Fabasoft.
“With its process-driven cloud platform, Fabasoft specializes in document-centric business workflows for manufacturing, financial services, as well as architecture, engineering, and construction. Among our strengths is efficient ‘low-code’ or ‘no-code’ customizing – in other words, tailoring our products to customer requirements without the need for elaborate programming. The broad range of standard interfaces also makes it easier to connect to existing IT systems,” explains Dangl.
Forrester Now Tech is an independent and objective overview of providers focusing on a specific IT solution area.
Download now: Now Tech: Content Platforms, Q1 2021
*Forrester Now Tech: Content Platforms, Q1 2021, Cheryl McKinnon with Daniel Hong, Hailey Colin, and Sam Bartlett.
Using the Fabasoft Business Process Cloud , companies can shape their business processes and work with digital content across organizations, IT infrastructures, and countries. Fabasoft Business Process Cloud’s out-of-the-box solutions and scalable applications empower organizations to bring the focus back to their customers as they move their digital transformation forward. Companies in the industrial sector appreciate the platform’s advantages, particularly when it comes to handling major projects and implementing processes in documentation and product management. Functionalities such as workflow automation and modeling, well-defined authorization and role models, transparent versioning, automatic synchronization, and mobile use facilitate collaboration and ensure seamless transparency.
About Fabasoft
Fabasoft is among the leading software product companies and cloud service providers in Europe for digital document management as well as electronic document, process, and records management. For more than three decades, numerous prominent private enterprises and public sector organizations have placed their trust in Fabasoft’s long-standing quality and experience.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210329005489/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 07:00:00 CEST | Press release
Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization Relfydess is approved in 33 markets and already launched in more than 20, including across Europe, the Middle East and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback Regulatory filings in other territories are ongoing and remain on track Ad hoc announcement pursuant to Art. 53 LR Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufa
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 03:45:00 CEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom